Company Overview and News
2018-08-02 seekingalpha - 1
Good day ladies and gentlemen and welcome. Thank you for standing by and welcome to Stoneridge, Second Quarter 2018 Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call maybe recorded.
AMETEK, Inc. (AME - Free Report) reported second-quarter 2018 adjusted earnings of 83 cents per share, beating the Zacks Consensus Estimate by 5 cents and also surpassed management’s guided range of 76-78 cents per share. Further, the figure increased 28% from the year-ago quarter and 6.4% sequentially. Net sales increased 14.1% on a year-over-year basis and 3.4% sequentially to $1.21 billion, driven by robust organic growth and strong contribution from acquisitions.
CWH MU GPN TRIP AME SRI
Yandex N.V. (YNDX - Free Report) reported second-quarter 2018 adjusted earnings of 24 cents (RUB 101.25) per share missing the Zacks Consensus Estimate by couple of cents. However, the figure surged 20% on a year-over-year basis and 14.3% sequentially. Revenues came in $472.8 million (RUB 29.7 billion), lagging the Zacks Consensus Estimate of $476 million. The figure exhibited year-over-year growth of 26.
CWH MU GPN TRIP SRI
As we explore global retirement trends through our quarterly Defined Contribution in Review, a notable difference between regions includes the greenish tinge to global plans, with a number of factors bolstering the Environmental, Social and Governance (ESG) standards outside of the U.S.
Square, Inc. (SQ - Free Report) is slated to report second-quarter 2018 results on Aug 1. The company’s comprehensive commerce ecosystem will continue to bolster its presence in the digital payment space globally. Notably, this ecosystem allows the sellers to combine software, hardware and payments services in order to accept payment from the customers through the company’s wide range of online payment products Moreover, Square’s focus on expansion of financial services offering is anticipated to be a significant growth driver backed by increasing demand for payments processing and mobile-commerce services among small businesses worldwide.
SQ MU ADI SRI
Cypress Semiconductor Corporation (CY - Free Report) delivered second-quarter 2018 non-GAAP earnings of 33 cents beating the Zacks Consensus Estimate by 4 cents. The figure surged 57.1% on a year-over-year basis and 22.3% sequentially. Revenues came in $624.1 million, surpassing the Zacks Consensus Estimate of $620 million. The figure also exhibited year-over-year growth of 5.1% and quarter-over-quarter improvement of 7.
ALGN CY MU ADI SRI SAH
Fortive Corporation (FTV - Free Report) delivered second-quarter 2018 earnings of 91 cents per share, surpassing the Zacks Consensus Estimate by two cents. The figure increased 28.2% from the year-ago quarter and 16.7% on a sequential basis. The figure also came ahead of management’s guidance of 86-90 cents. Revenues surged 6.9% sequentially and 14.1% year over year to $1.86 billion. The figure also fared better than the Zacks Consensus Estimate of $1.
EA FTV MU ADI SRI NVR TRN
Expedia Group, Inc. (EXPE - Free Report) delivered robust second-quarter 2018 adjusted earnings of $1.38 per share, surpassing the Zacks Consensus Estimate of 91 cents. The figure also compared favorably with the loss of 46 cents incurred in the previous quarter and increased a whopping 55.1% on a year-over-year basis. Revenues increased 14.7% sequentially and 11.2% on a year-over-year basis to $2.
EXPE EA MU ADI SRI NVR TRN
TE Connectivity Ltd. (TEL - Free Report) delivered third-quarter fiscal 2018 adjusted earnings of $1.43 per share, beating the Zacks Consensus Estimate by 6 cents. Notably, this marked the company’s 11th consecutive earnings beat. The figure also grew 15.3% year over year and steered past the projected range of $1.35-$1.37. Continued solid execution of the company’s strategic plans resulted in impressive earnings.
TWTR ADI TEL SRI
Investors interested in Electronics - Miscellaneous Components stocks are likely familiar with Stoneridge (SRI - Free Report) and Littelfuse (LFUS - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
LFUS UPS SRI WM LAD
2018-06-27 zacks - 1
Have you been paying attention to shares of Stoneridge (SRI - Free Report) ? Shares have been on the move with the stock up 18% over the past month. SRI hit a new 52-week high of $37.20 in the previous session. Stoneridge has gained 60.9% since the start of the year compared to the 5.7% move for the Computer and Technology sector and the -5.6% year-to-date return for its peer group.
VPG.WI PVAC PVAYQ TEL PVA SRI LNR NOVT VPG
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to SRI / Stoneridge, Inc. on message board site Silicon Investor.
as of ET